Short-course radiation with liposomal irinotecan, anti–PD-1, and targeted therapy for locally recurrent rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, single-arm Phase 2 trial combining hypofractionated radiotherapy with eight cycles of NALIRIF (liposomal irinotecan) plus 5‑FU/leucovorin, an anti–PD‑1 antibody, and targeted therapy in patients with locally recurrent rectal cancer. Radiation dosing is short-course (25–40 Gy/5 fractions or 15–30 Gy/5 fractions for re-irradiation of pelvic recurrence) and 25–50 Gy/5 fractions for metastatic sites as needed. The primary endpoint is local objective response rate and secondary endpoints include extrapelvic objective response rate, complete response rate, R0 resection rate, duration of response, progression-free survival, and overall survival. After systemic and local therapy, a multidisciplinary team will decide whether patients proceed to radical surgery or continued systemic/local management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patient is 18-75 years old at the time of signing the informed consent form. ECOG performance status 0-1. MRI/enhanced CT confirmed pelvic recurrence. According to RECIST 1.1, there is at least one measurable pelvic lesion.

Distant metastasis lesions are no more than 5 and metastatic organ are no more than 3.

No prior radiotherapy within 6 month. Failed to oxaliplatin treatment in prior chemotherapy or chemoradiotherapy due to toxicity or progression.

Has an investigator determined life expectancy of at least 24 weeks. Demonstrate adequate organ function (bone marrow, liver, kidney and clotting function) within 7 days before the first administration without using blood products or hematopoietic stimulating factors.

Non pregnant or lactating patients. Effective contraceptive methods should be used during the study and within 6 months of the last administration.

Fully informed and willing to provide written informed consent for the trial.

Exclusion Criteria:

Previous immunotherapy or Irinotecan Hydrochloride Liposome treatment. Neutrophil \< 1.5×10\^9/L, PLT \< 100×10\^9/L (PLT \< 80×10\^9/L in patients with liver metastasis), or Hb \< 90g/L; blood transfusion within 2 weeks before enrollment is not allowed to meet the enrollment criteria.

TBIL \> 1.5 ULN, or TBIL \> 2.5 ULN in patients with liver metastasis. AST or ALT \> 2.5 ULN, or ALT and / or AST \> 5 ULN in patients with liver metastasis.

Cr \> 1.5 ULN, or creatinine clearance \< 50ml / min (calculated according to Cockcroft Gault formula).

APTT \> 1.5 ULN, PT \> 1.5 ULN (subject to the normal value of the clinical trial research center).

Serious electrolyte abnormalities. Urinary protein ≥ 2+, or 24-hour urine protein ≥1.0g/24h. Uncontrolled hypertension: SBP \>140mmHg or DBP \> 90mmHg. The presence of gastrointestinal diseases such as gastric or duodenal active ulcers, ulcerative colitis or unresected tumours with active bleeding; or other conditions likely to cause gastrointestinal bleeding or perforation; or unhealed gastrointestinal perforation or gastrointestinal fistula after surgical treatment.

A history of arterial thrombosis or deep vein thrombosis within 6 months; a history of bleeding or evidence of bleeding tendency within 2 months.

A history of heart disease within 6 months (including congestive heart failure, acute myocardial infarction, severe/unstable angina, coronary artery bypass grafting, cardiac insufficiency ≥ NYHA grade 2 and LVEF\<50%).

Uncontrolled malignant pleural effusion, ascites, or pericardial effusion. The presence of a clinically detectable second primary malignancy, or history of other malignancies within 5 years excluding adequately treated non-melanoma skin cancer, carcinoma in situ of cervix and superficial bladder tumour (non-invasive tumour, or carcinoma in situ, or T1).

A history of liver disease including, but not limited to HBV infection or HBV DNA positive(≥1×10\^4/ml), HCV infection or HCV DNA positive(≥1×10\^3/ml) and liver cirrhosis.

Pregnant or lactating women or women who may be pregnant have a positive pregnancy test before the first medication; Or the female participants themselves and their partners who were unwilling to implement strict contraception during the study period.

The investigator considers that the subject is not suitable to participate in this clinical study due to any clinical or laboratory abnormalities or compliance problems.

Serious mental abnormalities. The diameter of brain metastasis is greater than 3cm or the total volume is greater than 30cc.

Clinical or radiological evidence of spinal cord compression, or tumours within 3 mm of the spinal cord on MRI.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Zhen Zhang, MD, PhD — Fudan University
• Study coordinator: Zhen Zhang, MD, PhD
• Email: zhen_zhang@fudan.edu.cn
• Phone: 18801735029

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy dose escalation for unresectable locally recurrent rectal cancer

  This study tests whether increasing radiotherapy dose is safe and feasible for people with unresectable locally recurrent rectal cancer who cannot have surgery.

  Recruiting at 4 sites Catharina Ziekenhuis Eindhoven · Maastricht, Limburg and 5 other locations · NCT07721181

• Comparing two types of radiotherapy for locally recurrent rectal cancer

  This study is testing if a new type of radiotherapy combined with immunotherapy can help people with locally recurrent rectal cancer live longer without their cancer getting worse compared to standard radiotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06928584

• Stereotactic body radiation therapy for unresectable locally recurrent rectal cancer

  This will try high-precision stereotactic body radiation therapy (SBRT) to control unresectable locally recurrent rectal cancer in adults who cannot have curative surgery.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07297004

• Combining radiation therapy and PD-1 antibody for advanced rectal cancer

  This study is testing if combining a special type of radiation therapy with a new immune treatment can help people with advanced rectal cancer live longer and possibly become eligible for surgery.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT06767007

• Brachytherapy and Nivolumab Before Surgery for Rectal Cancer

  This small Phase II study tests whether targeted internal radiation therapy followed by two doses of nivolumab can be safely given before rectal cancer surgery to see if it helps the treatment work.

  Recruiting Phase 2 Sir Mortimer B. Davis - Jewish General Hospital · Montreal, Quebec · NCT07645118

• Camrelizumab with long-course chemoradiotherapy before surgery for locally advanced low rectal cancer (pMMR/MSS)

  This trial tests whether giving camrelizumab before and after long-course chemoradiotherapy helps people with locally advanced, pMMR/MSS low rectal cancer achieve a higher complete response and preserve the rectum.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07527026

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.